WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing in the development and cGMP manufacture of biologics, today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and global commercialization of biologic therapies.
This partnership unites DHCG’s comprehensive regulatory, CMC, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics consulting capabilities with Altruist Biologics’ end-to-end cGMP manufacturing infrastructure in China, spanning cell line development, process and analytical method development, formulation development, drug substance manufacturing, drug product manufacturing, and bioconjugation services including antibody-drug conjugates (ADCs). Together, the two organizations will offer client companies a cost-effective and streamlined pathway into clinical and commercial-scale biologics manufacturing, with particular emphasis on programs seeking to leverage China’s world-class biomanufacturing infrastructure.
Biologics manufacturing in China has emerged as a strategic priority for sponsors worldwide, driven by the country’s rapidly maturing regulatory environment, significant cost advantages, and world-class production infrastructure. Yet for companies based outside China, translating that opportunity into executable programs requires navigating a complex web of NMPA requirements, local quality systems, and CMC expectations that differ meaningfully from those of the FDA or EMA. This collaboration is designed to close that gap. Altruist Biologics operates advanced cGMP facilities in Suzhou and Hangzhou with a total production capacity of 232,000 liters, including four 20,000-liter bioreactors at its Hangzhou site. DHCG brings deep expertise guiding sponsors through the regulatory and CMC strategy required to access and succeed in Chinese and global markets.
